IDEAYA Biosciences Introduces Stock Options for New Employees Under Nasdaq Rule 5635(c)(4)

IDEAYA Biosciences Expands by Granting Stock Options

IDEAYA Biosciences, Inc., a recognized leader in precision medicine and oncology, is making significant strides to enhance its workforce. On May 28, 2026, the company's Compensation Committee, part of its Board of Directors, revealed the granting of 221,000 non-qualified stock options to six new employees. This strategic move aligns with Nasdaq Listing Rule 5635(c)(4) and highlights IDEAYA's commitment to attracting top talent in the competitive landscape of biotech.

The stock options, an integral part of IDEAYA’s 2023 Employment Inducement Incentive Award Plan, serve as an incentive specifically for those who are new to the organization or returning after a period of non-employment. This plan aims to create a robust and dedicated team focused on the company's mission: the discovery and development of targeted therapeutics for cancer treatment.

Each stock option comes at an exercise price of $29.34, reflecting the common stock's closing price on the Nasdaq at the time of the grant. The options are set to vest over a period of four years, with 25% becoming available after the first year and the remaining 75% vesting monthly for the next three years. This vesting schedule underscores IDEAYA's strategy of fostering long-term dedication among its staff, dependent on continued service to the company.

IDEAYA Biosciences stands out in the biotechnology industry due to its focus on synthetic lethality and antibody-drug conjugates (ADCs) for treating specific solid tumors. The company's innovative approach combines small-molecule drug discovery with extensive expertise in structural biology and bioinformatics. IDEAYA is dedicated to the advancement of personalized cancer therapies, which are designed to target the underlying genetic factors of the disease, thus improving treatment outcomes for patients.

The introduction of these stock options not only incentivizes new employees but also reinforces IDEAYA’s commitment to fostering a culture of innovation and collaboration within the organization. By investing in its workforce, IDEAYA aims to secure its position at the forefront of precision oncology, tackling the pressing challenges in cancer treatment.

As IDEAYA moves forward, it strives to deliver a new wave of precision therapies that promise improved effectiveness and personalization, ultimately changing the course of treatment for cancer patients worldwide. The company's future initiatives and advancements within the field will continue to be closely monitored by investors and stakeholders alike, as it seeks to enhance the quality of care for those affected by cancer.

For more information about IDEAYA Biosciences and updates on their ongoing projects, investors and interested parties are encouraged to follow their official communications or reach out through their investor relations contact, Dr. Joshua Bleharski, Chief Financial Officer, via email.